Posts tagged with "Agenus Inc (NASDAQ:AGEN)"

Which Has the Biggest Driving Force? AVEO Pharmaceuticals (AVEO), Agenus Inc (AGEN) and SHOPIFY INC (SHOP)

Posted by Saimoon May 22, 2015 0 Comment 3041 views

New York, NY – GDP INSIDER  –  05/22/2015. This article discusses three companies: AVEO Pharmaceuticals (NASDAQ:AVEO), Agenus Inc (NASDAQ:AGEN) and SHOPIFY INC NPV SUB A (NYSE:SHOP) AVEO Pharmaceuticals (NASDAQ:AVEO) increased by 39% in trading on Thursday, a move of $0.63 to $2.23.  Volume was up dramatically to 94.2 million shares compared to its 3 million […]

Negative ROI Companies: Agenus Inc (AGEN), Halozyme Therapeutics, Inc. (HALO), And BioDelivery Sciences International, Inc. (BDSI)

Posted by Ryan Mandell January 28, 2015 0 Comment 684 views

New York, NY – GDP INSIDER  – 01/28/2015. Agenus Inc (NASDAQ:AGEN)’s ROI now stands at -581.40%. The stock edged up slightly by 0.19%, gaining $0.01 to end the session at $5.26. The stock exchanged hands between $5.13 low and $5.39 high in the session. AGEN opened the session at $5.20, exchanged 1.15 million shares, a volume […]

Agenus Inc (NASDAQ:AGEN) Looses Sheen After Lung Cancer Trial Data Disappoints

Posted by Chris Bell March 21, 2014 0 Comment 960 views

Agenus Inc (NASDAQ:AGEN) saw its market valuation go down by a double digit margins yesterday. The trigger for the sell off could be traced to the Form 8K filing that the company did with SEC before markets opened yesterday. The filings related to the company updating the regulator about the reversal it has faced, in […]

Investors Not Happy With Agenus Inc (NASDAQ:AGEN)

Posted by Lynn Eisler March 10, 2014 0 Comment 1154 views

Agenus Inc (NASDAQ:AGEN), the small capped drug maker came out with a slew of announcements and regulatory filings in the intervening days of 5th to 7th March. The combined effect of these pronouncements which included 4Q and full year 2013 operations results, by the firm left its stock down by 8.16 percent during trading on […]

Investors Don’t Like Pricing Of Agenus Inc (NASDAQ:AGEN) Public Offering

Posted by George Brook February 6, 2014 0 Comment 1004 views

The $84 million market capped development stage biotech firm Agenus Inc (NASDAQ:AGEN) announced on 5th February that it has determined the selling price of its shares at the previously announced public offer of 19.3 million shares at $2.7 per share. This pricing was greeted with disappointment by the market in general, as the stock had […]